ArticleNature biomedical engineering2021
Directly reprogrammed natural killer cells for cancer immunotherapy.
Article in Nature biomedical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Next-generation natural killer cell therapy: bench to bedside and beyond.Signal transduction and targeted therapy · 2026Review
- Bandgap-Engineered PtAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2026Article
- Cell-free secretome of CD56Theranostics · 2026Article
- Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma.Journal of hematology & oncology · 2025Article
- Cell reprogramming: methods, mechanisms and applications.Cell regeneration (London, England) · 2025Review
- Lung Cancer Organoid System to Evaluate the Cytotoxicity of Natural Killer Cells.International journal of stem cells · 2025Article
- Tailoring cell-inspired biomaterials to fuel cancer therapy.Materials today. Bio · 2025Review
- Comparative dissection of transcriptional landscapes of human iPSC-NK differentiation and NK cell development.Life medicine · 2024Article
- Article
- Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation.Nanomaterials (Basel, Switzerland) · 2023Article
- Acid-switchable nanoparticles induce self-adaptive aggregation for enhancing antitumor immunity of natural killer cells.Acta pharmaceutica Sinica. B · 2023Article
- Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies.Cancers · 2023Article
- Self-Assembled Oleic Acid-Modified Polyallylamines for Improved siRNA Transfection Efficiency and Lower Cytotoxicity.ACS applied bio materials · 2023Article
- CAR-NK cell therapy for glioblastoma: what to do next?Frontiers in oncology · 2023Review
- Review
- Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.Frontiers in immunology · 2022Review
- Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies.Archivum immunologiae et therapiae experimentalis · 2021Review
- Reprogrammed anti-tumor NK cells.Nature methods · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficacious and accessible sources of natural killer (NK) cells would widen their use as immunotherapeutics, particularly for solid cancers. Here, we show that human somatic cells can be directly reprogrammed into NK cells with a CD56
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.